HR Execs on the Move


 
CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.caredx.com
  • 1 Tower Place 9th Floor
    South San Francisco, CA USA 94080
  • Phone: 415.287.2300

Executives

Name Title Contact Details
Liam Pickett
Head of National Sales, Patient and Testing Profile
Abhishek Jain
Chief Financial Officer - Interim Profile
Lexi Bojansky
Regional Sales Director Profile
Curt Lind
Vice President, Head of Research & Development - Lab Products Profile
Dustin Leach
Vice President Customer Experience Profile

Similar Companies

XOMA

XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies.  The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody.  XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program in place to identify other IL-1 mediated diseases that could be treated with gevokizumab.  One of these POC studies led XOMA to select its next Phase 3 indication, pyoderma gangrenosum, a rare ulcerative skin disease. XOMA`s scientific research also produced the XMet program, which consists of three classes of preclinical allosteric modulating antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of diabetes.  XOMA will retain the compound that has potential to treat several rare insulin dysfunction-related diseases and to out-license the compounds that could address the diabetes markets. 

Gene Link Inc

Gene Link Inc is a Hawthorne, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

bioMASON

We build with carbon the same way nature does. Our biocement® materials are healthier for us and the Planet.

HudsonAlpha Institute for Biotechnology

HudsonAlpha Institute seeks to expand the science of human genomics and hasten its movement into the marketplace where discoveries can benefit society.

Nano Mark

Nano Mark, Llc is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.